Core Points - Beijing Tianxing Medical Co., Ltd. (referred to as "Tianxing Medical") has had its IPO terminated, which was intended for the Sci-Tech Innovation Board, with an initial fundraising target of 880 million yuan [2] - The company specializes in innovative medical devices for sports medicine, focusing on the research, production, and sales of implants, active devices, consumables, and surgical tools [4] - Tianxing Medical's revenue for 2021, 2022, and 2023 was 73.01 million, 148 million, and 241 million yuan respectively, with net profits of -110 million, 40.34 million, and 63.58 million yuan [4] Financial Summary - For the first nine months of 2024, Tianxing Medical reported revenue of 222.93 million yuan and a net profit of 64.08 million yuan [5] - The company's total assets increased from 282.02 million yuan in 2021 to 550.99 million yuan by September 30, 2024, while the equity attributable to shareholders rose from 233.64 million yuan to 446.13 million yuan over the same period [5] - The asset-liability ratio decreased from 18.68% in 2022 to 16.20% in 2024, indicating improved financial stability [5] Shareholder Structure - The largest shareholder, Dong Wenxing, holds 33.14% of the shares directly and controls 41.47% of the voting rights through various entities [6] - Other significant shareholders include Xiamen Defu (10.64%), Suzhou Junlian (9.71%), and Aobo Capital (9.28%) [8][9] - Post-IPO, Dong Wenxing's direct shareholding will decrease to 24.86%, while Xiamen Defu's will drop to 7.98% [9]
天星医疗IPO被终止：年营收2.4亿拟募资8.8亿 君联资本是股东
Sou Hu Cai Jing·2025-06-06 11:04